AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12112177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg OD)
Number of subjects: 22
Study 12112177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10025743 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy Patch Test (APT) with 3000 to 10,000 PNU/g of Dermatophagoides pteronyssinus, cat dander, grass, birch, and mugwort pollen allergen extracts in petrolatum
Number of subjects: 253
Study 10025743 — intervention group
Group type: COMPARATOR
Intervention: Skin prick test
Number of subjects: 253
Study 10025743 — intervention group
Group type: COMPARATOR
Intervention: Radioallergosorbent test (RAST)
Number of subjects: 253
Study 8703659 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled magnesium sulphate (0, 90, 135, 180, 360 mg)
Number of subjects: 39
Study 2180331 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg daily)
Number of subjects: 222
Study 2180331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 101316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (800 mg/day for 1 week or a single dose of 1.0 g by mouth)
Number of subjects: 20
Study 101316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (by inhalation)
Number of subjects: 20
Study 7058674 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine aspartate (250 mg/dg/day for one week)
Number of subjects: 5
Study 7058674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30312812 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 48
Study 30312812 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (Control)
Number of subjects: 48
Study 29217376 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC5288 (Zika virus and Japanese encephalitis virus chimera)
Number of subjects: 125
Study 29217376 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC5283 (wild-type Zika virus)
Number of subjects: 125
Study 29217376 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC5283 (wild-type Zika virus) via split-dose needle-free injection
Number of subjects: 125
Study 26965174 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Intervention (ICBI); n=88
Number of subjects: 177
Study 26965174 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU); n=89
Number of subjects: 177
Study 25253174 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/bid)
Number of subjects: 200
Study 25253174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 22731240 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 129
Study 22731240 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron in combination with dexamethasone
Number of subjects: 129
Study 22731240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 22731240 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 129
Study 20831698 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg q.i.d.
Number of subjects: 36
Study 20831698 — intervention group
Group type: COMPARATOR
Intervention: Placebo q.i.d.
Number of subjects: 36
Study 20831698 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg b.i.d.
Number of subjects: 36
Study 18159905 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent topical steroids
Number of subjects: 0
Study 18159905 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapies
Number of subjects: 0
Study 18159905 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel immunomodulatory therapeutic approaches
Number of subjects: 0
Study 16129209 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calcium session (L-HF) with calcium ion concentration of 2.5 mEq/L (1.25 mmol/L)
Number of subjects: 12
Study 16129209 — intervention group
Group type: COMPARATOR
Intervention: High-calcium session (H-HF) with calcium ion concentration of 3.5 mEq/L (1.75 mmol/L)
Number of subjects: 12
Study 11815895 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antioxidant micronutrient mixture (beta-carotene 18 mg/day, vitamin C 750 mg/day, vitamin E 600 mg/day)
Number of subjects: 297
Study 11815895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 10070054 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose concentration at 4 mmol/l
Number of subjects: 10
Study 10070054 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose concentration at 9 mmol/l
Number of subjects: 10
Study 7734364 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 9
Study 7734364 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 1849133 — intervention group
Group type: EXPERIMENTAL
Intervention: OKY-046 (thromboxane A2 synthetase inhibitor)
Number of subjects: 11
Study 6997220 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation group
Number of subjects: 58
Study 6997220 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 31416357 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation plus platelet inhibition (OAC+PI)
Number of subjects: 4042
Study 31416357 — intervention group
Group type: COMPARATOR
Intervention: Platelet inhibition only
Number of subjects: 4042
Study 30348124 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese (BMI ≥ 28.0 kg/m2)
Number of subjects: 32482
Study 30348124 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (24.0 ≤ BMI < 28.0 kg/m2)
Number of subjects: 32482
Study 30348124 — intervention group
Group type: COMPARATOR
Intervention: Normal weight (18.5 ≤ BMI < 24.0 kg/m2)
Number of subjects: 32482
Study 26917112 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r 800/100 mg once daily
Number of subjects: 27
Study 26917112 — intervention group
Group type: COMPARATOR
Intervention: ATV/r 300/100 mg once daily
Number of subjects: 27
Study 23845099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention (six-month duration)
Number of subjects: 240
Study 23845099 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 240
Study 21842159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (0.75 mg DMT/kg bodyweight)
Number of subjects: 9
Study 21842159 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 9
Study 19398067 — intervention group
Group type: EXPERIMENTAL
Intervention: 3g of oral Myelophil per day
Number of subjects: 36
Study 17124249 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care with annual hospital review (SCSC)
Number of subjects: 100
Study 17124249 — intervention group
Group type: COMPARATOR
Intervention: Aggressive treatment delivered in hospital (ATH)
Number of subjects: 100
Study 16239811 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruption of the infrapatellar fat pad contour on lateral radiographs
Number of subjects: 14
Study 16239811 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine lateral view radiographs
Number of subjects: 14
Study 12037070 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir treatment arm
Number of subjects: 0
Study 12037070 — intervention group
Group type: COMPARATOR
Intervention: Dual-nucleoside treatment arm
Number of subjects: 0
Study 12037070 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir treatment arm (plasma HIV-1 RNA <500 copies/ml)
Number of subjects: 0
Study 12037070 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir treatment arm (plasma HIV-1 RNA >or=500 copies/ml)
Number of subjects: 0
Study 12037070 — intervention group
Group type: EXPERIMENTAL
Intervention: Samples with plasma RNA levels <50 copies/ml
Number of subjects: 0
Study 12016904 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin dispersible tablet (formulation A)
Number of subjects: 10
Study 12016904 — intervention group
Group type: COMPARATOR
Intervention: conventional tablet (formulation B)
Number of subjects: 10
Study 8551026 — intervention group
Group type: COMPARATOR
Intervention: Nursing reorganization including intensified handwashing, single-use equipment, and waste control.
Number of subjects: 64
Study 8551026 — intervention group
Group type: COMPARATOR
Intervention: Nursing procedures before reorganization (control group).
Number of subjects: 64
Study 8551026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing reorganization procedures post-implementation.
Number of subjects: 64
Study 2173646 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 199
Study 2173646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 199
Study 2173646 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate (prior 2-year period)
Number of subjects: 199
Study 2173646 — intervention group
Group type: EXPERIMENTAL
Intervention: No drug therapy between shocks
Number of subjects: 199
Study 210476 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg chlorpromazine
Number of subjects: 24
Study 210476 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg chlorpromazine
Number of subjects: 24
Study 210476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31240721 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vessel segmentation and removal using two cascaded CNNs
Number of subjects: 50
Study 31240721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel removal method
Number of subjects: 50
Study 27518129 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond laser (PSL)
Number of subjects: 21
Study 27518129 — intervention group
Group type: COMPARATOR
Intervention: Nanosecond laser (NSL)
Number of subjects: 21
Study 27518129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PSL and NSL
Number of subjects: 21
Study 24875927 — intervention group
Group type: EXPERIMENTAL
Intervention: HDTBR with countermeasures (centrifugation or aerobic exercise)
Number of subjects: 22
Study 24875927 — intervention group
Group type: COMPARATOR
Intervention: HDTBR without countermeasures
Number of subjects: 22
Study 24020660 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive cooling (Coolgard®)
Number of subjects: 80
Study 24020660 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive cooling (Arctic Sun®)
Number of subjects: 80
Study 21516308 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 1691
Study 18653496 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1.5 mg kg(‐1)
Number of subjects: 54
Study 18653496 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (C)
Number of subjects: 54
Study 16525746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (Fleet)
Number of subjects: 225
Study 16525746 — intervention group
Group type: COMPARATOR
Intervention: Picoprep (sodium picosulfate-based preparation)
Number of subjects: 225
Study 12525827 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa; NovoSeven®) administered as a 90- to 110-μg/kg bolus dose every second hour.
Number of subjects: 6500
Study 12525827 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa; NovoSeven®) administered for major surgery and life-threatening bleeding.
Number of subjects: 6500
Study 12525827 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa; NovoSeven®) with longer intervals between doses after the first 24 hours.
Number of subjects: 6500
Study 12525827 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa; NovoSeven®) at higher doses in in vitro experiments.
Number of subjects: 6500
Study 10770171 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological study (hydrocortisone infusion for 48 h in a pulsatile and diurnal pattern)
Number of subjects: 7
Study 10770171 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant study (same total dose of hydrocortisone as physiological study, but with pulses of equal magnitude spaced evenly)
Number of subjects: 7
Study 10770171 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed study (same total dose of hydrocortisone, but with diurnal pattern shifted 12 h)
Number of subjects: 7
Study 10770171 — intervention group
Group type: COMPARATOR
Intervention: Baseline study (saline infusion for 48 h)
Number of subjects: 7
Study 8851456 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg CR oxycodone tablet every 12 hours for 4 days
Number of subjects: 24
Study 8851456 — intervention group
Group type: COMPARATOR
Intervention: 5 mL of 1-mg/1 mL IR oxycodone solution every 6 hours for 4 days
Number of subjects: 24
Study 1471584 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by district nurse after hospital discharge
Number of subjects: 344
Study 1471584 — intervention group
Group type: COMPARATOR
Intervention: Usual discharge procedures (Control)
Number of subjects: 344
Study 6726654 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine with cimetidine (300 mg every 6 hr)
Number of subjects: 6
Study 30161278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralized solvent-dehydrated bone allograft (SDBA)
Number of subjects: 44
Study 30161278 — intervention group
Group type: COMPARATOR
Intervention: Mineralized freeze-dried bone allograft (FDBA)
Number of subjects: 44
Study 29101022 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD
Number of subjects: 20
Study 29101022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26002590 — intervention group
Group type: EXPERIMENTAL
Intervention: α-tocopherol supplementation
Number of subjects: 89
Study 26002590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 25555856 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 60
Study 25555856 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiobook
Number of subjects: 60
Study 25555856 — intervention group
Group type: COMPARATOR
Intervention: Control (silence)
Number of subjects: 60
Study 23615090 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (extratemporal resections)
Number of subjects: 60
Study 23615090 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete resection of ictal onset areas
Number of subjects: 60
Study 23615090 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of acute postoperative seizures
Number of subjects: 60
Study 22009369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of lipopolysaccharide (LPS, 4 ng/kg)
Number of subjects: 0
Study 22009369 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 18295324 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming program
Number of subjects: 116
Study 18295324 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 116
Study 18295324 — intervention group
Group type: COMPARATOR
Intervention: Behavioural intervention
Number of subjects: 116
Study 18295324 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116
Study 16767525 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg daily nasal hPTH(1-34) spray for 3 months
Number of subjects: 90
Study 16767525 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg daily nasal hPTH(1-34) spray for 3 months
Number of subjects: 90
Study 16767525 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 microg daily nasal hPTH(1-34) spray for 3 months
Number of subjects: 90
Study 16767525 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplements of 300 mg calcium and 200 IU vitamin D(3)
Number of subjects: 90
Study 14517200 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (10 mg oral dose) alone
Number of subjects: 21
Study 14517200 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (10 mg oral dose) administered 4 hours after CsA (300 mg oral dose)
Number of subjects: 21
Study 14517200 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (300 mg oral dose) alone
Number of subjects: 21
Study 14517200 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (10 mg oral dose)
Number of subjects: 21
Study 11225965 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 0
Study 11225965 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (10 mg/day)
Number of subjects: 0
Study 11225965 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (20 mg/day)
Number of subjects: 0
Study 11225965 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin (20 mg/day)
Number of subjects: 0
Study 11225965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9200296 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (cholecystectomy)
Number of subjects: 501
Study 9200296 — intervention group
Group type: COMPARATOR
Intervention: Observation (conservative treatment)
Number of subjects: 501
Study 7827590 — intervention group
Group type: EXPERIMENTAL
Intervention: Indole-3-carbinol (I3C) 400 mg/day for 3 months
Number of subjects: 60
Study 7827590 — intervention group
Group type: COMPARATOR
Intervention: Alpha-cellulose 20 g/day for 3 months
Number of subjects: 60
Study 7827590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3402101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton wool earplugs covered with petroleum jelly
Number of subjects: 30
Study 3402101 — intervention group
Group type: COMPARATOR
Intervention: Water instillation (1 drop 0.05 ml, 2 drops 0.1 ml, or no water)
Number of subjects: 30
Study 30008392 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting intervention with a focus on experiential goals
Number of subjects: 556
Study 30008392 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning by stating intentions
Number of subjects: 556
Study 30008392 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to instrumental goals
Number of subjects: 556
Study 30008392 — intervention group
Group type: COMPARATOR
Intervention: Repeated pairing of goals with the school meal
Number of subjects: 556
Study 28526374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (500,000 IU total over 5 days)
Number of subjects: 30
Study 28526374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (250,000 IU total over 5 days)
Number of subjects: 30
Study 28526374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28526374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (both doses)
Number of subjects: 30
Study 26232311 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-L polyethylene glycol-citrate-simethicone plus 2-day bisacodyl
Number of subjects: 400
Study 26232311 — intervention group
Group type: COMPARATOR
Intervention: 4-L polyethylene glycol
Number of subjects: 400
Study 24827127 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 2.0 mg/m² on day 1 with erlotinib 150 mg on days 2-16 (21-day regimen)
Number of subjects: 123
Study 24827127 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m² on days 1 and 8 with erlotinib 150 mg on days 15-28 (28-day regimen)
Number of subjects: 123
Study 22533456 — intervention group
Group type: EXPERIMENTAL
Intervention: Website usability testing with 21 patients
Number of subjects: 103
Study 22533456 — intervention group
Group type: EXPERIMENTAL
Intervention: Website evaluation by 103 patients
Number of subjects: 103
Study 22533456 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet access among participants
Number of subjects: 103
Study 22533456 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a differentiating factor
Number of subjects: 103
Study 20102890 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 40 mg/day orally (n = 43)
Number of subjects: 86
Study 20102890 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 43)
Number of subjects: 86
Study 18600119 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective nursing interventions conducted daily for 45 to 60 minutes after the 7th to 10th day of chemotherapy
Number of subjects: 60
Study 18600119 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing interventions
Number of subjects: 60
Study 15999048 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human antithrombin III (75 U/kg)
Number of subjects: 52
Study 15999048 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 52
Study 12177105 — intervention group
Group type: EXPERIMENTAL
Intervention: Motexafin gadolinium (5.0 mg/kg/d for 10 days) administered before each radiation treatment
Number of subjects: 25
Study 10615219 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA diet (38% energy as fat, 18% as MUFA, 10% as saturated fatty acids)
Number of subjects: 53
Study 10615219 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA diet
Number of subjects: 53
Study 10615219 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 53
Study 10615219 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA diet and Control diet
Number of subjects: 53
Study 9411973 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the term 'smoker's lung' in communication with patients (intervention group, n = 25)
Number of subjects: 56
Study 9411973 — intervention group
Group type: COMPARATOR
Intervention: Traditional terminology used in communication (control group, n = 31)
Number of subjects: 56
Study 1472933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine and lomustine (experimental arm)
Number of subjects: 0
Study 1472933 — intervention group
Group type: COMPARATOR
Intervention: Busulfan (conventional treatment)
Number of subjects: 0
Study 1472933 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (hydrea or busulfan)
Number of subjects: 0
Study 4028625 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal therapeutic system of scopolamine (TTS-S)
Number of subjects: 49
Study 4028625 — intervention group
Group type: COMPARATOR
Intervention: Transdermal placebo (TD-P)
Number of subjects: 49
Study 31326951 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking for 30 minutes at an average speed of 3 km/h on the last night before surgery.
Number of subjects: 85
Study 31326951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no walking on the last night before surgery).
Number of subjects: 85